Journal of Clinical and Experimental Hematopathology最新文献_第8页

Clinico-pathological profile of patients with plasma cell neoplasms with special reference to bone marrow fibrosis and amyloid deposition. 浆细胞肿瘤患者的临床病理特征，特别是骨髓纤维化和淀粉样沉积。

IF 1.5

Journal of Clinical and Experimental Hematopathology Pub Date : 2023-01-01 DOI: 10.3960/jslrt.23029

Narasimhapriyan Kannan, Jasmita Dass, Sahitya Dangudubiyyam, Ganesh Kumar Viswanathan, Mukul Aggarwal, Pradeep Kumar, Rishi Dhawan, Tulika Seth, Manoranjan Mahapatra

{"title":"Clinico-pathological profile of patients with plasma cell neoplasms with special reference to bone marrow fibrosis and amyloid deposition.","authors":"Narasimhapriyan Kannan, Jasmita Dass, Sahitya Dangudubiyyam, Ganesh Kumar Viswanathan, Mukul Aggarwal, Pradeep Kumar, Rishi Dhawan, Tulika Seth, Manoranjan Mahapatra","doi":"10.3960/jslrt.23029","DOIUrl":"10.3960/jslrt.23029","url":null,"abstract":"To clarify the significance of bone marrow fibrosis and amyloid deposition in plasma cell neoplasm, a retrospective cross-sectional study for a period of 3 years was conducted. Patients who underwent bone marrow aspiration and biopsy with suspicion of plasma cell neoplasms were included in the study. The bone marrow findings were correlated with clinical profile of the patient along with biochemical parameters, cytogenetics, Fluorescent in situ hybridization (FISH) wherever available. A total of 273 bone marrow aspirates and biopsies of patients with suspected plasma cell neoplasms were analyzed. There were 181 male patients and 92 female patients (Male: Female = 1.96: 1). There were 245 cases of multiple myeloma (89.7%), 8 cases of primary amyloidosis (2.9%) and 6 monoclonal gammopathy of undetermined significance (MGUS) (2.1%), 5 cases of plasmacytoma (1.8%) and 4 cases of smouldering myeloma (1.4%), 5 cases of POEMS syndrome (1.8%). Bone marrow fibrosis was noted in 12 patients at diagnosis (4.3%). Among the parameters studied, only the mean Hemoglobin was significantly low in patients with marrow fibrosis. Amyloid deposition in various organs including bone marrow, kidney, liver etc., were noted in 17 patients overall (6.2%). In conclusion, the incidence of fibrosis (4.3%) and amyloidosis (6.2%) associated with plasma cell neoplasms were much lower in our study as compared to published studies.","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"63 4","pages":"214-218"},"PeriodicalIF":1.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10861367/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139040705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High-grade B-cell lymphoma with 11q aberrations: A single-center study. 11q畸变的高级别b细胞淋巴瘤:一项单中心研究

IF 1.5

Journal of Clinical and Experimental Hematopathology Pub Date : 2023-01-01 DOI: 10.3960/jslrt.23007

Shoki Yamada, Yuka Oka, Moe Muramatsu, Yuko Hashimoto

{"title":"High-grade B-cell lymphoma with 11q aberrations: A single-center study.","authors":"Shoki Yamada, Yuka Oka, Moe Muramatsu, Yuko Hashimoto","doi":"10.3960/jslrt.23007","DOIUrl":"https://doi.org/10.3960/jslrt.23007","url":null,"abstract":"High-grade B-cell lymphoma with 11q aberrations (HGBL-11q) has been classified for the first time as a high-grade mature B-cell neoplasm according to the 5th edition of the World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues. HGBL-11q is morphologically and immunohistochemically similar to Burkitt lymphoma (BL) or HGBL; it is characterized by gain in the 11q23.2-11q23.3 region and loss in the 11q24.1-qter region but it lacks MYC translocation. HGBL-11q is a rare tumor, and its exact frequency in Japan remains unclear. In this study, we classified 113 Germinal center B-cell (GCB) type aggressive B-cell lymphomas (BCLs), which were divided into BL, high-grade (HG), and large cell (LC) morphologies. We performed fluorescence in situ hybridization (FISH) to identify 11q aberrations. Nine patients had 11q aberrations (7.96%, 9/113), including six HGBL-11q. The age range was from 8 to 87 years, and all were male. Six out of 14 patients with HG morphology were diagnosed with HGBL-11q (6/14, 42.9%). HGBL-11q has been found to occur primarily in children and young adults but also in middle-aged and older adults. Patients with HG morphology without MYC translocation should undergo FISH for 11q aberrations regardless of age. However, the pathogenesis, clinical findings, and prognosis of HGBL-11q remain unclear. The accumulation of cases with an accurate HGBL-11q diagnosis in daily practice and accurate and detailed data on HGBL-11q will contribute to further understanding of 11q aberrations.","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"63 2","pages":"121-131"},"PeriodicalIF":1.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/29/09/jslrt-63-121.PMC10410621.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9970680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic impact of miR-125b and miR-155b and their relationship with MYC and TP53 in diffuse large B-cell lymphoma: cell-of-origin classification matters. 弥漫性大B细胞淋巴瘤中miR-125b和miR-155b的预后影响及其与MYC和TP53的关系：起源细胞分类问题。

IF 1.5

Journal of Clinical and Experimental Hematopathology Pub Date : 2023-01-01 DOI: 10.3960/jslrt.23009

Eduardo Henrique Cunha Neves Filho, Stella Barbanti Zancheta, Paulo Goberlânio de Barros Silva, Rommel Mario Rodríguez Burbano, Silvia Helena Barem Rabenhorst

{"title":"Prognostic impact of miR-125b and miR-155b and their relationship with MYC and TP53 in diffuse large B-cell lymphoma: cell-of-origin classification matters.","authors":"Eduardo Henrique Cunha Neves Filho, Stella Barbanti Zancheta, Paulo Goberlânio de Barros Silva, Rommel Mario Rodríguez Burbano, Silvia Helena Barem Rabenhorst","doi":"10.3960/jslrt.23009","DOIUrl":"10.3960/jslrt.23009","url":null,"abstract":"Tumoral microRNAs, such as miR-125b and miR-155b, are important gene expression regulators with complex pathogenetic mechanisms. However, their role in DLBCL, especially when cell-of-origin classification is considered, are still to be elucidated. In a series of 139 DLBCL cases considering germinal center (GC) versus nonGC subtypes, we investigated miR-125b and miR-155b expression by in situ hibridization and their association with some immunophenotypic presentations, including MYC, BCL2 and TP53 expression, MYC, BCL2 and BCL6 translocation status, as well as clinicopathological features and outcomes. miR-125b detection was positively correlated to the Ki-67 index (P = 0.035) in the nGC. Considering the GC subgroup, the percentage of miR-125b positive cells was also correlated to either MYC and MYC/BCL2 double expression (P = 0.047 and P = 0.049, respectively). When it comes to nGC patients, miR-155b percentage and intensity, as well as Allred score, were positively correlated to disease progression (P = 0.038, P = 0.057 and P = 0.039, respectively). In a multivariate analysis, GC phenotype was a significant independent factor associated with higher OS (P = 0.007) and, considering the nGC group, although not significant, the expression of TP53, miR-125b and miR-155b seems to be potential prognostic biomarkers in these tumors. This study demonstrated different pathways based on cell-of-origin classification and highlighted different clinical outcomes. miR-125b, miR-155b and TP53 expression may also represent potential prognostic factors in nGC-DLBCL.","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"63 3","pages":"164-172"},"PeriodicalIF":1.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628825/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41137469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Precursory or early lesions of follicular lymphoma: clinical features, pathology, and genetics. 滤泡性淋巴瘤的先兆或早期病变:临床特征、病理和遗传学。

IF 1.5

Journal of Clinical and Experimental Hematopathology Pub Date : 2023-01-01 DOI: 10.3960/jslrt.23010

Naoki Oishi

{"title":"Precursory or early lesions of follicular lymphoma: clinical features, pathology, and genetics.","authors":"Naoki Oishi","doi":"10.3960/jslrt.23010","DOIUrl":"https://doi.org/10.3960/jslrt.23010","url":null,"abstract":"Follicular lymphoma (FL) is an indolent B-cell lymphoma with a germinal center (GC) B cell phenotype that typically harbors t(14;18)(q32;q21). t(14;18) juxtaposes IGH on 14q32 and BCL2 on 18q21, resulting in overexpression of the anti-apoptotic BCL2 protein. However, t(14;18) is also found in the peripheral blood or lymphoid nodes (LNs) of otherwise healthy individuals. Moreover, overt FL has several additional gene alterations involved in epigenetic modification, JAK/STAT signaling, immune modulation, and NF-κB signaling, indicating multi-step lymphomagenesis in FL. There are two early or precursory lesions of FL: t(14;18)-positive cells in the peripheral blood of otherwise healthy individuals and in situ follicular B-cell neoplasm (ISFN). t(14;18)-positive cells are found in 10%-50% of healthy populations, and their incidence and frequency increase with age. The detection of t(14;18) in peripheral blood is a predictive factor for an increased risk of overt FL development. In contrast, ISFN is a histopathologically recognizable precursory lesion, in which t(14;18)-positive cells are confined to the GC of otherwise reactive LNs. ISFN is usually detected incidentally, with an incidence ranging from 2.0% to 3.2%. Occasional ISFN cases have concurrent or metachronous clonally related overt FL or aggressive B-cell lymphoma of a GC phenotype. t(14;18)-positive cells in peripheral blood and isolated ISFN, by themselves, are asymptomatic with limited clinical significance; however, investigations of t(14;18)-positive precursory or early lesions offer meaningful insights into the pathogenesis of FL. This review summarizes the epidemiology, clinical features, pathology, and genetics of precursory or early lesions of FL.","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"63 2","pages":"65-72"},"PeriodicalIF":1.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a4/a7/jslrt-63-65.PMC10410625.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10342669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic approach for classic Hodgkin lymphoma in small samples with an emphasis on PD-L1 expression and EBV harboring in tumor cells: a brief review from morphology to biology. 小样本经典霍奇金淋巴瘤的诊断方法，重点是PD-L1表达和EBV在肿瘤细胞中的窝藏:从形态学到生物学的简要回顾

IF 1.5

Journal of Clinical and Experimental Hematopathology Pub Date : 2023-01-01 DOI: 10.3960/jslrt.23003

Taishi Takahara, Ayako Sakakibara, Yuta Tsuyuki, Akira Satou, Seiichi Kato, Shigeo Nakamura

{"title":"Diagnostic approach for classic Hodgkin lymphoma in small samples with an emphasis on PD-L1 expression and EBV harboring in tumor cells: a brief review from morphology to biology.","authors":"Taishi Takahara, Ayako Sakakibara, Yuta Tsuyuki, Akira Satou, Seiichi Kato, Shigeo Nakamura","doi":"10.3960/jslrt.23003","DOIUrl":"https://doi.org/10.3960/jslrt.23003","url":null,"abstract":"Classic Hodgkin lymphoma (CHL) was first described in 1832 by Thomas Hodgkin, and is characterized by a small number of Hodgkin and Reed-Sternberg cells in a rich inflammatory background. However, even in this modern era, due to the histological and biological overlap with CHL and other B-cell malignancies, including mediastinal grey zone lymphoma and other lymphomas accompanied by \"Hodgkinoid cells\", their discrimination is challenging and sometimes impossible. The complexity and ambiguity of the boundaries of CHL and its related diseases make the definition of CHL unresolved. Our group has studied the significance of PD-L1 expression and infection of Epstein-Barr virus (EBV) in the diagnosis of CHL, emphasizing their pathological role, clinical significance, and high reproducibility even in daily clinical practice. In this review, we summarize the diagnostic strategy of CHL and its histological lookalikes based on neoplastic PD-L1 expression and infection of EBV, and attempt a reappraisal of the definition of CHL.","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"63 2","pages":"58-64"},"PeriodicalIF":1.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/da/9c/jslrt-63-58.PMC10410620.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10342676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world efficacy of DA-EPOCH-R/HD-MTX regimen in CD5-positive diffuse large B cell lymphoma: a single-institute analysis. DA-EPOCH-R/HD-MTX方案治疗cd5阳性弥漫性大B细胞淋巴瘤的实际疗效:一项单研究所分析

IF 1.5

Journal of Clinical and Experimental Hematopathology Pub Date : 2023-01-01 DOI: 10.3960/jslrt.22035

Kohtaro Toyama, Keita Nakayama, Sachie Terasaki, Ikuko Matsumura, Shuhei Kanaya, Hiromasa Iino, Hiroyuki Noguchi, Kenichi Tahara, Takatomo Yoshida, Akio Saito

{"title":"Real-world efficacy of DA-EPOCH-R/HD-MTX regimen in CD5-positive diffuse large B cell lymphoma: a single-institute analysis.","authors":"Kohtaro Toyama, Keita Nakayama, Sachie Terasaki, Ikuko Matsumura, Shuhei Kanaya, Hiromasa Iino, Hiroyuki Noguchi, Kenichi Tahara, Takatomo Yoshida, Akio Saito","doi":"10.3960/jslrt.22035","DOIUrl":"https://doi.org/10.3960/jslrt.22035","url":null,"abstract":"CD5-positive diffuse large B cell lymphoma (CD5+ DLBCL) is a high-risk lymphoma type. Recently, the PEARL5 (a Phase II trial of DA-EPOCH and Rituximab with HD-MTX therapy for newly diagnosed DLBCL with CD5 expression) study demonstrated the efficacy of the DA-EPOCH-R (cyclophosphamide, etoposide, doxorubicin, vincristine, prednisone, and rituximab)/HD-MTX (high-dose methotrexate) regimen for CD5+ DLBCL. In this report, we revealed the impact of the DA-EPOCH-R/HD-MTX regimen on the clinical course of CD5+ DLBCL in the real-world. We retrospectively compared CD5+ and CD5- DLBCL patients diagnosed from January 2017 to December 2020 and analyzed their clinicopathological characteristics, treatment, and prognosis. There was no difference in age, sex, clinical stage, and cell of origin; however, the CD5-positive group had higher lactate dehydrogenase levels and a worse performance status than the CD5-negative group (p=0.00121 and p=0.0378, respectively). International prognostic index (IPI) was worse in the CD5-positive group than in the CD5-negative group (p=0.0498), but NCCN-IPI (National Comprehensive Cancer Network-IPI) was no different between the two groups. The CD5-positive group was more frequently treated with the DA-EPOCH-R/HD-MTX regimen than the CD5-negative group (p =0.001857). Complete remission rate and 1-year overall survival did not differ between the CD5-positive and -negative groups (90.0% vs 81.4%, p=0.853; 81.8% vs 76.9%, p=0.433). We conclude that the DA-EPOCH-R/HD-MTX regimen is effective for CD5+ DLBCL in this single institute analysis.","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"63 1","pages":"19-24"},"PeriodicalIF":1.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e4/3e/jslrt-63-19.PMC10158721.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9414224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Histologic transformation of follicular lymphoma: pathologists' viewpoint. 滤泡性淋巴瘤的组织学转变:病理学家的观点。

IF 1.5

Journal of Clinical and Experimental Hematopathology Pub Date : 2023-01-01 DOI: 10.3960/jslrt.22046

Akiko Miyagi Maeshima

{"title":"Histologic transformation of follicular lymphoma: pathologists' viewpoint.","authors":"Akiko Miyagi Maeshima","doi":"10.3960/jslrt.22046","DOIUrl":"https://doi.org/10.3960/jslrt.22046","url":null,"abstract":"Outcomes of patients with histologic transformation (HT) of follicular lymphoma (FL) have been believed to be poor. The most common histologic subtype of transformation from FL is diffuse large B-cell lymphoma (DLBCL), which accounts for 90% of the cases, and the remaining 10% of the cases include classic Hodgkin lymphoma, high-grade B-cell lymphoma, plasmablastic lymphoma, B-acute lymphoblastic leukemia/lymphoma, histiocytic/dendritic cell sarcoma, and anaplastic large cell lymphoma-like lymphoma. Because the histologic criteria for the diagnosis of DLBCL transformed from FL are unclear, convenient histopathological criteria for HT are required. One of the proposed criteria of HT from our institute is the presence of diffuse architecture with a proportion of large lymphoma cells of ≥20%, and for challenging cases, Ki-67 index ≥50% is used as a reference. Patients with HT to non-DLBCL have poorer outcomes than those with HT to DLBCL; thus, rapid and accurate histologic diagnosis is desired. In this review, we discussed the recent literatures describing the histopathologic variety and proposal of definition of HT.","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"63 1","pages":"12-18"},"PeriodicalIF":1.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/46/cf/jslrt-63-12.PMC10158720.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9414225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of rapidly fatal TAFRO syndrome-like features in a patient with essential thrombocythemia. 原发性血小板增多症患者快速致命TAFRO综合征样特征的发展

IF 1.5

Journal of Clinical and Experimental Hematopathology Pub Date : 2023-01-01 DOI: 10.3960/jslrt.22029

Hiroko Iizuka-Honma, Haruko Takizawa, Hideaki Nitta, Toru Mitsumori, Masaaki Noguchi

{"title":"Development of rapidly fatal TAFRO syndrome-like features in a patient with essential thrombocythemia.","authors":"Hiroko Iizuka-Honma, Haruko Takizawa, Hideaki Nitta, Toru Mitsumori, Masaaki Noguchi","doi":"10.3960/jslrt.22029","DOIUrl":"https://doi.org/10.3960/jslrt.22029","url":null,"abstract":"TAFRO syndrome is a rare systemic inflammatory disease characterized by thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly. We encountered a case of calreticulin mutation-positive essential thrombocythemia (ET) with TAFRO syndrome-like features, followed by a rapid fatal course. The patient had been on anagrelide therapy for approximately three years for management of ET; however, she suddenly stopped going for follow-up and discontinued the medicine for a year. She presented with fever and hypotension, suggestive of septic shock, and was transferred to our hospital. The platelet count at the time of admission to another hospital was 50 × 104 / μL; however, it decreased to 25 × 104 / μL upon transfer to our hospital and further decreased to 5 × 104 / μL on the day of her death. In addition, the patient showed remarkable systemic edema and progression of organomegaly. Her condition suddenly worsened and led to her death on the 7th day of hospitalization. Postmortem, serum and pleural effusion interleukin (IL)-6 and vascular endothelial growth factor (VEGF) levels were significantly increased. Consequently, a diagnosis of TAFRO syndrome, since she met the diagnostic criteria for clinical findings and had high cytokine concentrations. Dysregulation of cytokine networks has also been reported in ET. Therefore, concurrent ET and TAFRO syndrome may have further triggered cytokine storms and contributed to the aggravation of the disease on development of TAFRO syndrome. To the best of our knowledge, this is the first report of complications seen in a patient with TAFRO syndrome due to ET.","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"63 1","pages":"32-36"},"PeriodicalIF":1.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e7/e6/jslrt-63-32.PMC10158723.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9418352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evidence for distinct mechanisms of immune suppression in EBV-positive and EBV-negative Hodgkin lymphoma. EBV阳性和EBV阴性霍奇金淋巴瘤免疫抑制机制不同的证据。

IF 1.5

Journal of Clinical and Experimental Hematopathology Pub Date : 2023-01-01 DOI: 10.3960/jslrt.23037

Makka Adam, Yonas Bekuretsion, Amha Gebremedhin, Anna Kwiecinska, Rawleigh Howe, Beyene Petros, Mats Jerkeman

{"title":"Evidence for distinct mechanisms of immune suppression in EBV-positive and EBV-negative Hodgkin lymphoma.","authors":"Makka Adam, Yonas Bekuretsion, Amha Gebremedhin, Anna Kwiecinska, Rawleigh Howe, Beyene Petros, Mats Jerkeman","doi":"10.3960/jslrt.23037","DOIUrl":"10.3960/jslrt.23037","url":null,"abstract":"Epstein Barr Virus (EBV) has been recognized for its ability to transform B lymphocytes and for its association with different types of cancers including Hodgkin lymphoma. In addition, EBV may also modulate the microenvironment of HL. In this study, we aimed to investigate the prevalence of EBV among HL cases in Ethiopia and to assess the tissue cellular composition of EBV-related and EBV-unrelated cases. We constructed a tissue microarray (TMA) of 126 consecutive cases of classical HL (CHL) and nodular lymphocyte predominant HL (NLPHL) from a tertiary cancer centre, Tikur Anbessa Hospital, Addis Ababa, Ethiopia, and evaluated a panel of immunohistochemical markers. The quantification of immune cells was performed using HALO 2.3, a platform for image analysis from Indica Lab Inc. A total of 77/126 (61.1%) of HL cases expressed LMP1/EBER. Infiltration of CD8+, T-bet+ and FoxP3+ cells was higher in the microenvironment of EBV-related CHL, with P values of <0.001, <0.001 and <0.016, respectively. In contrast, the expression of PD1 was higher in the microenvironment of EBV-unrelated CHL cases (P < 0.001). Unlike in Western countries, the majority of HL cases in Ethiopia were associated with EBV. As FoxP3+ and PD1-expressing cells are thought to participate in down regulation of the immune response by different mechanisms, this finding highlights the previously unrecognized possibility that distinct immunosuppressive mechanisms may be ongoing within EBV positive and negative HL types. This may have important prognostic and therapeutic implications.","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"63 4","pages":"230-239"},"PeriodicalIF":1.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10861371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139040707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Methotrexate-induced subacute myelopathy: a serious but treatable complication. 甲氨蝶呤诱发的亚急性脊髓病：一种严重但可治疗的并发症。

IF 1.5

Journal of Clinical and Experimental Hematopathology Pub Date : 2023-01-01 DOI: 10.3960/jslrt.23041

Takashi Miyoshi, Tadakazu Kondo, Momoko Nishikori, Toshio Kitawaki, Katsuya Kobayashi, Masakazu Fujimoto, Noriyoshi Yoshinaga, Satoshi Oka, Kohsuke Asagoe, Shinsaku Imashuku, Akifumi Takaori-Kondo

{"title":"Methotrexate-induced subacute myelopathy: a serious but treatable complication.","authors":"Takashi Miyoshi, Tadakazu Kondo, Momoko Nishikori, Toshio Kitawaki, Katsuya Kobayashi, Masakazu Fujimoto, Noriyoshi Yoshinaga, Satoshi Oka, Kohsuke Asagoe, Shinsaku Imashuku, Akifumi Takaori-Kondo","doi":"10.3960/jslrt.23041","DOIUrl":"10.3960/jslrt.23041","url":null,"abstract":"Subacute myelopathy is a rare but serious complication of methotrexate (MTX) that may cause paraplegia. Although its underlying mechanisms have not been fully elucidated, homocysteine is thought to play a role in the pathogenesis of this adverse effect. Herein, we report the case of a 34-years old female patient with diffuse large B-cell lymphoma who developed progressive paraplegia accompanied by dysfunctional bladder and bowel movements after treatment with a modified CODOX-M/IVAC regimen, including high-dose intravenous MTX and intrathecal (IT-) MTX. Neurological symptoms gradually improved to almost normal levels within 4.5 months of onset following treatment with a combination of S-adenosylmethionine, methionine, cyanocobalamin, and folate. During chemotherapy, including high-dose MTX and IT-MTX for hematological malignancies, MTX-induced subacute neuronal damage should be carefully evaluated, and appropriate treatment should be initiated as early as possible.","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"63 4","pages":"251-256"},"PeriodicalIF":1.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10861375/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139040709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0